SUMMARY -Th e prevalence of chronic hepatitis C increases in elderly patients. Th e aims of this study were to identify the factors associated with hepatocellular carcinoma (HCC) and end-stage liver disease development and to evaluate the effi cacy and safety of pegylated interferon (PEG-IFNα) plus ribavirin (RBV) therapy in elderly patients. A retrospective cohort study included all consecutive patients with hepatitis C virus (HCV) infection treated with PEG-IFNα+RBV between 2003 and 2013. Elderly patients had a higher frequency of poor prognostic factors including genotype 1 infection, high fi brosis, and high fi brosis index based on four factors (FIB-4) score. Th e sustained virologic response (SVR) rate for genotype 1 was signifi cantly lower (35.8% vs. 57.1%), while the frequency of PEG-IFNα (27.2% vs. 7.8%), RBV dose reduction (19.6% vs. 9.7%) and treatment discontinuation (13.0% vs. 4.1%) was signifi cantly higher in elderly patients. However, age was not associated with SVR in multivariate analysis, and comparable SVR rates were achieved when adjusted for fi brosis score (Ishak ≤3: 66.7% vs. 69.8%). During the follow-up, HCC was diagnosed in 18 elderly patients (3 SVR+, 4 SVR-and 9 untreated patients). In conclusion, selected elderly patients can achieve comparable SVR rates as younger patients, but with a higher rate of side eff ects. Since complications of HCV infection occur more frequently in elderly patients, they should be given priority for antiviral therapy.
Introduction
Chronic hepatitis C (CHC) continues to be a major public health problem. Despite the limited number of population-based studies on the age-specifi c prevalence, HCV prevalence increases with age, and currently the age group with the peak prevalence in Europe is the 55-65 age group 1, 2 . While the mean life expectancy in the European Union (EU) is 19.8 years once a man reaches the age of 65 (according to the EuroStat), it is expected that HCV related liver cirrhosis and hepatocellular carcinoma (HCC) will dramatically increase in the following years, particularly in the elderly population 3 . Aging is considered as an unfavorable factor for liver disease progression; adults older than 60 more often present with complications of cirrhosis and HCC as initial manifestations of HCV infection; older age at the time of initial infection is associated with more rapid progression to fi brosis, cirrhosis and infectious complications; elderly patients are at an increased risk of HCC, even if they achieve sustained viral response (SVR) in the absence of signifi cant fi brosis or cirrhosis [4] [5] [6] . Although this age group was excluded from the initial pegylated interferon plus ribavirin (PEG-IFNα+RBV) registration trials, these studies identifi ed age ≥60 years to be associated with poorer treatment response 7, 8 . Th e safety and effi cacy of HCV therapies have been extensively studied in patients between the ages of 18 and 60, but elderly patients remain an understudied and diffi cult-to-treat population. Th e 'real-life' studies of PEG-IFNα+RBV treatment in elderly individuals are scarce. Although generally thought as a negative predictor of SVR, the published results of therapy effi cacy in elderly patients are disagreeing. While some studies showed the treatment to be well tolerated and there was little or no diff erence in SVR, other showed marked reduction in SVR rates 6, [9] [10] [11] [12] . Nevertheless, older age is still associated with a lower likelihood of being considered for antiviral therapy 13, 14 . Not long ago, direct acting antiviral agents (DAAs) that markedly increase SVR have been licensed, but the effi cacy and toxicity of these drugs in elderly population is still unknown. Importantly, due to the price concerns, it is unlikely that this treatment will soon become widely available in low-income countries. Th us, the ways of stratifying patients that might benefi t from PEG-IFNα+RBV backbone therapy are of high importance.
Th erefore, we performed a retrospective cohort study to examine disease progression in elderly patients treated with PEG-IFNα+RBV as compared with treatment naïve elderly patients and to identify factors associated with HCC and end-stage liver disease (ESLD) development. Th e secondary aim was to evaluate PEG-IFNα+RBV treatment response and safety in elderly patients (≥60 years).
Patients and Methods

Study design and population
In order to analyze treatment response and safety profi le of PEG-IFNα and RBV combination therapy in elderly population, a retrospective cohort study that included 577 consecutive adult, treatment-naïve patients that started combination therapy between January 2003 and January 2013 was conducted at the Croatian Reference Center for Viral Hepatitis, Zagreb, Croatia. Patients were stratifi ed by age into two groups: those aged ≥60 (n=92, 15.9%) and those aged <60 years (n=485, 84.1%).
To determine the impact of PEG-IFNα+RBV treatment and achievement of SVR on the clinical outcomes of HCV infection in elderly population (≥60 years), all consecutive CHC patients enrolled between 2003 and 2013 were included in the study. In total, 142 patients were included in the cohort that was followed for 3.56±1.87 years. Patients were stratifi ed in three categories: SVR group, non-SVR group and untreated patients. Selected endpoints were development of HCC, ESLD, and progression of liver disease, as measured by the aspartate aminotransferase-to-platelet ratio index (APRI) and fi brosis index based on four factors (FIB-4) scores.
Data collection and defi nitions
Records of all patients treated at the Department of Viral Hepatitis, University Hospital for Infectious Diseases, Zagreb (UHID) during the study period were extracted and used for collection of clinical and laboratory data. Patients were treated either with PEG-IFNα2a 180 μg/week (n=334, 57.9%) or PEGIFNα2b 1.5 μg/week (n=243, 42.1%) plus weight-adjusted RBV. Th e duration of therapy in HCV genotypes 1 and 4 was 48 weeks, and in genotypes 2 and 3 it was 24 weeks. Th erapy was discontinued in patients with genotype 1 and genotype 4 if the viral load decreased by less than 2 log HCV RNA copies/mL at week 12 compared with baseline values and if HCV RNA was still detectable at week 24.
Th e following demographic and laboratory data were analyzed: age, gender, baseline hemoglobin concentration, white blood cell count (WBC), absolute neutrophil count (ANC), platelet count, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total serum protein and serum albumin, pretreatment HCV viremia, and genotype. HCV RNA quantifi cation was performed by COBAS Ampliprep/ COBAS TaqMan HCV test (Roche Diagnostics, Diagnostic Systems, Pleasanton, CA, USA). HCV genotyping was performed by VERSANT HCV Genotyping assay (LIPA, Bayer Diagnostics, Puteaux, Cedex, France). Liver biopsy was performed in a total of 427 patients and the Ishak scoring system was used as an indicator of histologic activity 15 . Th e APRI and FIB-4 scores were calculated for all patients and were used as a surrogate marker of disease severity 16, 17 . Th e primary outcome measured was SVR achievement defi ned as undetectable HCV RNA at 24 weeks after the end of antiviral therapy. Secondary outcomes were rates of adverse events, rates of PEG-IFNα and/or RBV dose modifi cations and treatment discontinuation. In order to evaluate disease progression in elderly patients, data on the development of HCC, APRI, FIB-4 score and ESLD were retrieved from medical records of all patients that had ≥60 years at the time of diagnosing HCV at UHID between 2003 and 2013. Th e diagnosis of HCC was confi rmed on the basis of a verifi ed focal liver lesion by imaging techniques in accordance with the European Association for the Study of the Liver guidelines 18 . Th is study was conducted according to the ethical guidelines of the Declaration of Helsinki and was approved by the UHID Ethics Committee.
Statistical analysis
Demographic and clinical characteristics and laboratory data were evaluated and presented descriptively. Th e χ 2 -test with Yates correction, Fisher exact test and Mann Whitney U test were used to compare the groups, as appropriate. All tests were two-tailed; a p<0.05 was considered statistically signifi cant. Binary logistic regression analysis was used to assess the independent predictors of SVR. Cumulative incidence of HCC was estimated by the Kaplan-Meier method. Th e prognostic relevance of clinical variables and HCC occurrence was evaluated by univariate analysis with the log-rank test and by multivariate Cox regression analysis. Th e time frame for each outcome was defi ned as the time from diagnosing HCV infection until the onset of the event. Data were censored when individuals died from non-liver-related causes, received a liver transplant, or were lost during follow-up. Th e strengths of association were expressed as odds ratio (OR) and the corresponding 95% confi dence interval (95%CI). Statistical analyses were performed using Prism (ver. 5.0) statistical software (Graphpad Software, San Diego, CA, USA) and MedCalc for Windows®, ver. 11.5.1.0 (MedCalc Software, Mariakerke, Belgium).
Results
Baseline characteristics of treated patients
A total of 346 men and 231 women aged 18-73 years (44.18±12.6) were included in the study. Patients aged ≥60 comprised 15.9% of the study population. Table 1 .
Elderly patients were more often infected with HCV genotype 1 (88.0%), had more severe histologic activity of the disease, as well as higher FIB4-score and lower platelet count and hemoglobin level. Importantly, elderly patients more frequently had comorbidities (65.2%), including hypertension (n=42, 45.7%), diabetes (n=9, 9.8%), chronic obstructive pulmonary disease (n=10, 10.9%), hyperlipidemia (n=24, 26.1%), coronary disease (n=13, 14.1%), and osteoporosis (n=7, 7.6%). Although six (6.5%) patients had chronic renal impairment, none of our patients was treated with chronic dialysis.
Treatment safety, modifi cations and discontinuation
Th erapy had to be adapted in a substantial number of elderly patients. Reduction of PEG-IFNα and RBV was more frequently required and treatment was more frequently prematurely discontinued due to side eff ects in elderly patients. Data on treatment discontinuation and side eff ects are summarized in Table 2 .
Neutropenia (≤1500 cells/μL), anemia and thrombocytopenia (≤50x10 9 /L) more frequently developed in the elderly group. In addition, during the course of treatment, a decreased level of hemoglobin, ANC and platelets was more pronounced than in younger patients. Th e mean decrease in hemoglobin was 39.73±25.71g/L in elderly versus 26.46±12.33g/L in younger patients (p=0.0265). Th e incidence of both anxiety and insomnia was higher in elderly patients. Th ere was no lethal outcome in either group during the treatment or in the 6-month follow-up period.
Treatment outcome
Th e analysis included data on all patients who received at least one dose of medication (intention-totreat analysis). In the whole group, SVR was achieved in 339 (62.4%) patients; SVR rate was 53.8% for genotype 1 and 80.1% for genotype 3.
In elderly patients, SVR rate was signifi cantly lower for genotype 1 (35.8% vs. 57.1%, p=0.0007), while there was no statistical signifi cance for genotype 3 
Factors associated with sustained viral response
In order to identify if age ≥60 is independently associated with lower SVR, we performed multiple logistic regression analysis taking confounders into account. All predictors were entered in a backward stepwise logistic regression model with the SVR being the dependent variable (antiviral therapy (PEG-IFNα2a vs. PEG-IFNα2b), age (<60 years vs. ≥60 years), gender, body weight (≤75 kg vs. >75 kg), HCV-genotype 3 vs. non-3, extent of fi brosis (mild fi brosis: Ishak 0-3 vs. signifi cant fi brosis: Ishak 4-6)). Statistically nonsignifi cant predictors were progressively excluded based on the likelihood ratio test. Multivariable model showed that age had no signifi cant infl uence on SVR. As expected, the best SVR predictor was genotype 3, while signifi cant fi brosis and RBV reduction were negatively associated with SVR, as shown in Table 4 .
Similar results were obtained in subgroup analysis that focused on genotype 1, signifi cant fi brosis and RBV reduction. When only genotype 1 patients were included, fi brosis (OR 0.26, 95%CI 0.15-0.45, p<0.0001) and RBV reduction (OR 0.37, 95%CI 0.18-0.77, p=0.0074) had a negative impact on SVR, while PEG-IFNα-2a treatment was positively associated with SVR (OR 1.99, 95%CI 1.15-3.43, p<0.0132). Next, we performed subgroup analysis on patients with signifi cant fi brosis (Ishak ≥4) . Th e fi nal multivariable model included genotype 3 (OR 17.75, 95%CI 2.06-152.28), PEG-IFNα reduction (OR 0.09, 95%CI 0.01-0.75) and female sex (OR 2.62, 95%CI 1.26-6.70), but again age was not found to be an independent predictor of SVR. 
Incidence of heptatocellular carcinoma and disease progression in elderly patients
Of the 577 patients that received PEG-IFNα+RBV treatment in the study period, 256 (44.4%) patients were followed-up for more than 12 months after the end of treatment (98 SVR+ and 158 SVR-patients, with the mean follow-up of 4.57±2.71 years). Seventeen patients developed HCC at the mean age of 56.21±11.66 years, corresponding to the incidence rate of 1.95 per 100 person-years. HCC was diagnosed in four patients that achieved SVR; in two patients within 1 year after SVR, and in the other two at 3 and 4 years, respectively, after achieving SVR. HCV RNA was tested at the diagnosis of HCC in all four of these patients, and they all were negative; two patients had Ishak fi brosis score 3, one patient had Ishak 4 and one Ishak 5; none had varices or decompensated liver disease at the time of HCC diagnosis. FIB-4 score >3.25 (HR 4.57, 95%CI 1.65-12.61, p=0.0035) and age ≥60 (HR 10.56, 95%CI 2.64-42.15, p=0.0009) were found to signifi cantly infl uence HCC incidence.
To further determine the impact of PEG-IFNα+RBV treatment on the clinical outcomes of HCV infection in elderly population, we collected additional data from untreated CHC patients that were aged ≥60 at the time of fi rst presentation at UHID between 2003 and 2013 and that were followed-up for at least 12 months. Overall, 142 patients were identifi ed and included in the cohort (76 untreated and 66 treated) that was followed-up for 3.56±1.87 years. During the follow-up, HCC developed in three patients with SVR, four patients from non-SVR group and nine untreated patients, corresponding to the incidence of 3.6, 4.7 and 5.0 per 100 person-years, respectively. Cox proportional hazard regression analysis identifi ed only baseline FIB-4 >3.25 (HR 12.1, 95%CI 3.78-38.71, p<0.0001) to be independently associated with HCC development, while sex, PEG-IFNα+RBV treatment and SVR were not associated with HCC in elderly patients. Of 142 patients enrolled, 111 (78.1%) and 86 (60.5%) patients had both year 2 and year 4 APRI and FIB-4 levels available, respectively. Th ere were no signifi cant diff erences in APRI and FIB-4 progression between non-SVR and untreated patients; during 4 years, the proportion of patients with stage 3 APRI (>1.0) and FIB-4 (>3.25) increased from 34% and 24% at baseline to 41% and 38% at year 4, respectively (Fig.  1) . Any event of disease decompensation (ascites, encephalopathy and/or variceal bleeding) developed in one patient from non-SVR group and in seven (9.21%) untreated patients.
Discussion
Th e combination of pegylated interferon and ribavirin still remains the backbone or even standard therapy in many resource-limited settings. Since the access to IFN free treatment is restricted, the way of prioritizing patients for treatment is of high importance. Interestingly, neither EASL nor AASLD in recently updated HCV treatment guidelines highlight elderly population for early treatment, refl ecting the defi ciency of studies performed in this understudied group 19, 20 . While the safety and effi cacy of PEG-IFNα+RBV therapy have been extensively reviewed, the perception of poorer outcomes and the potential diffi culties associated with adherence and drug interactions have resulted in limited access for elderly patients. Results of our study show that older age is associated with several negative predictors of treatment response, such as higher fi brosis score, FIB-4 score, genotype 1 infection and longer duration of infection. Th is is in clear contrast to other risk groups in Croatia, traditionally considered 'diffi cult-to-treat', such as war veterans or intravenous drug users 21, 22 . In addition, more comorbidities have been observed in elderly patients, mainly metabolic and cardiovascular diseases. According to multivariate analysis, signifi cant fi brosis, RBV reduction and genotype 1, but not the age, were associated with SVR. Response rates were high among elderly patients with genotype 1 infection and mild fi brosis (66%) and comparable with younger group. Similar results have been reported from France, Italy, Canada and the USA 6, 10, 12, 23 . Meanwhile, reports from Japan consistently report lower SVR rates in elderly patients 11, 13 . Although some of these studies had been performed before IL28B genotyping was recommended, this diff erence in response rates might be explained with diff erences in gene polymorphisms. Since the majority of patients from our cohort had been treated before IL28B genotyping was introduced, we did not include IL28B genotype in our analysis.
Huang et al. suggest that poor adherence is the major reason for treatment inferiority in elderly patients and that SVR of 67% and 80% can be reached in genotype 1 infected elderly patients, if their treatment lasts for ≥80% of its expected duration and if they achieve rapid virologic response (RVR), respectively 24 . In addition, analysis of our genotype 1 subgroup showed that fi brosis, RBV dose reduction and treatment with PEG-IFNα-2a, but not the age, were independent factors associated with treatment effi cacy.
Th e results of our study also confi rmed that elderly patients had a higher incidence of dose reduction, mainly due to neutropenia, thrombocytopenia and anemia 10, 23, 24 . Th e most frequent age-specifi c side effects were anxiety and insomnia in up to 52% of elderly patients, but in contrast to other studies, severe depression occurred in a minority of elderly patients (4%) [23] [24] [25] . Importantly, treatment completion rate in our study was 86.9% in the elderly and 95.9% in the younger group. Th ese rates are signifi cantly higher than previously reported in similar 'real-life' studies that had treatment discontinuation rate of 21% to 53% 10, 24 . Overall, it seems that selected elderly patients can be treated with PEG-IFNα+RBV therapy, and achieve similar response rates as younger patients, with careful monitoring and management of more frequent side eff ects. Nevertheless, PEG-IFNα+RBV still remains an option for genotype 1 infected patients with positive predictors of treatment response (RVR, F1-F2 fi brosis and IL28 CC genotype) in many countries.
Th e long-term benefi ts of virologic cure are well known; SVR is associated with a more than 70% reduction in the risk of HCC and 90% reduction in the risk of liver-related mortality and liver transplantation [26] [27] [28] . However, the impact of age on HCV eradication and HCC development is still debatable. Th e mean age of HCC patients has been progressively increasing over the last decades and in Europe it is currently reaching a peak at 70 years 18 . We examined the occurrence of HCC in our treated cohort that corresponds to the incidence of 1.95 per 100 person-years. While FIB-4 score >3.25 and age ≥60 were significantly associated with HCC development, SVR did not signifi cantly reduce the incidence of HCC. Several studies have previously reported that advanced age at HCV eradication is a risk factor for HCC development in SVR patients 5, 26, 27 . Bruno et al. report that male sex and age >54 have a higher risk of developing HCC after SVR, suggesting that host-related factors and duration of the infection increase the risk of HCC 29 . Similarly, a study from Japan identifi ed age >55 at HCV eradication and heavy alcohol intake to be independently associated with the development of HCC within 5 years after HCV eradication, but longterm risk of developing HCC remains for up to 15 years 30 . Our study showed that in elderly population, the risk of HCC was higher in both treated and naïve patients as compared with younger patients, thus highlighting this population and the importance of early antiviral treatment in this group. Importantly, a proportion of patients with FIB-4 >3.25 signifi cantly increased in a 4-year period, increasing this risk even more. Recent reports argue the earlier initiation of treatment in patients with Metavir F0 and F1, which are recognized in current guidelines as a group in which treatment can be postponed; a long-term follow-up study recorded signifi cantly better 15-year survival rates for SVR patients than for those whose treatment had failed or for those who remained untreated 31 . Th e retrospective nature of this study may have represented a potential source of selection bias that might overestimate the incidence of HCC and SVR rates since our Center serves as the Referral Center for Viral Hepatitis in Croatia. Th e signifi cant number of lost-to-follow-up might represent information bias. However, the rates of SVR and HCC incidence in our study were consistent with those obtained in similar studies, as stated above.
In conclusion, the risk of disease progression and HCC development in elderly patients with CHC underscores the need for early treatment of this 'diffi cultto-treat' group. Although elderly patients often have worse prognostic factors and more frequent side eff ects to PEG-IFNα+RBV therapy, a subset of elderly patients can be safely treated with close monitoring, and may achieve comparable SVR rates as younger patients. Since older age is strongly associated with faster fi brosis progression, HCC and reduced quality of life, elderly patients should not be excluded from assessment for treatment a priori. In the Croatian HCV treatment guidelines, elderly patients are now prioritized for antiviral therapy. Due to the persistent longterm risk of HCC in elderly patients, even after achievement of SVR, surveillance should be continued over a prolonged period.
